1 Value Stock on Our Watchlist and 2 We Turn Down

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored.

Forward P/E Ratio: 7.8x

Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.

Why Does AMPH Fall Short?

1. Smaller revenue base of $723.3 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy

2. Efficiency has decreased over the last two years as its adjusted operating margin fell by 4.3 percentage points

At $28.57 per share, Amphastar Pharmaceuticals trades at 7.8x forward P/E. Check out our free in-depth research report to learn more about why AMPH doesn’t pass our bar.

Forward P/E Ratio: 9.2x

Founded in 1937 by Thomas Rowe Price Jr., who pioneered the growth stock investing approach, T. Rowe Price (NASDAQ:TROW) is an investment management firm that offers mutual funds, advisory services, and retirement planning solutions to individuals and institutions.

Why Are We Cautious About TROW?

1. Annual revenue growth of 3.5% over the last five years was below our standards for the financials sector

2. Incremental sales over the last five years were less profitable as its earnings per share were flat while its revenue grew

T. Rowe Price is trading at $94.03 per share, or 9.2x forward P/E. If you’re considering TROW for your portfolio, see our FREE research report to learn more.

Forward P/S Ratio: 2.3x

With its technology powering interactions with 6.2 billion monthly active users across the digital landscape, Braze (NASDAQ:BRZE) provides a platform that helps brands build and maintain direct relationships with their customers through personalized, cross-channel messaging and engagement.

Why Do We Like BRZE?

1. Annual revenue growth of 25.6% over the past two years was outstanding, reflecting market share gains

2. Billings growth has averaged 22.4% over the last year, indicating a healthy pipeline of new contracts that should drive future revenue increases

3. Forecasted revenue growth of 19.2% for the next 12 months indicates its momentum over the last two years is sustainable

Braze’s stock price of $17.86 implies a valuation ratio of 2.3x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.

The market’s up big this year – but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking – and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.